The U.S. Patent and Trademark Office on Tuesday issued a patent to Endonovo Therapeutics for usage of its SofPulse technology in stroke victims.

The Woodland Hills company makes therapeutic devices that send electric pulses to a targeted area of the body. The company hopes its technology will replace opioids for pain management.

“We are extremely pleased with the continued development and expansion of our patent portfolio,” Alan Collier, chief executive of Endonovo, said in a statement. “This new issuance continues to expand the breadth and depth of our SofPulse unit.”

The company plans to market SofPulse products to help with neuroinflammation from stroke, which affects more than 795,000 people in the U.S. every year.